TROGARZO Drug Profile

Summary for Tradename: TROGARZO

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TROGARZO

Recent Clinical Trials for TROGARZO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
TaiMed Biologics Inc.	Phase 3
Westat	Phase 3

See all TROGARZO clinical trials

Pharmacology for TROGARZO

Mechanism of Action	CD4-directed Antibody Interactions HIV 1 Post-attachment Fusion Inhibitors
Established Pharmacologic Class	CD4-directed Blocking Antibody Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor
Chemical Structure	Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TROGARZO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TROGARZO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TROGARZO Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for TROGARZO

Last updated: February 20, 2026

What is TROGARZO?

TROGARZO (ibalizumab-uiyk) is a humanized monoclonal antibody approved by the FDA in 2018 for treating multidrug-resistant (MDR) human immunodeficiency virus (HIV-1) infection in adults. It acts by blocking HIV entry into CD4+ T cells, providing a novel mechanism for treatment-resistant cases.

Current Market Position

TROGARZO entered a niche segment targeting patients with limited treatment options. Its market share remains modest but growing, driven by increasing prevalence of MDR-HIV and guidelines favoring novel agents for resistant cases. As of 2022, sales approximated $100 million in the U.S. (IQVIA, 2023).

Market Drivers

• Increase in MDR-HIV cases: The CDC estimates about 4-5% of HIV patients develop drug resistance. MDR-HIV requires complex regimens, bringing TROGARZO into focus for specialized treatment (CDC, 2021).

• FDA approvals in expanded indications: The FDA granted TROGARZO breakthrough therapy designation and expanded approvals to include more resistant strains, extending its potential market (FDA, 2020).

• Reimbursement pathways: CMS and private insurers recognize TROGARZO's use in resistant HIV cases, supporting market access.

• Combination therapy protocols: TROGARZO is used with other antiretrovirals, with ongoing clinical trials exploring its role in broader HIV populations.

Competitive Landscape

Drug	Mechanism	Indicated Population	Market Share (2022)
TROGARZO	CD4-directed antibody	MDR-HIV patients	2-3% of HIV market
Ibalizumab (TROGARZO)	HIV entry inhibitor	Multidrug-resistant HIV	Niche, resistant subset
Dolutegravir (Tivicay)	Integrase inhibitor	Broad HIV population	Dominant, 60% of HIV market
Cabotegravir (ViiV)	Integrase inhibitor/long-acting	Prevention and treatment	Growing segment

Note: TROGARZO's niche status limits its market penetration.

Revenue Projections and Growth Potential

Projected revenues depend on drug resistance trends, approval extensions, and pricing strategies.

• Pricing: List price per dose (800 mg) exceeds $50,000, with typical treatment requiring 2-3 doses per month (ClinCalc, 2022).

• Market penetration: Assuming 25-30% of MDR-HIV patients receive TROGARZO by 2025, revenue estimates could reach $300-400 million annually.

• Growth factors:

  • Expansion of FDA labels for broader or resistant populations.
  • Deployment in combination therapies.
  • Increased screening for resistance leading to more diagnoses.

• Constraints:

  • High treatment cost.
  • Competition from emerging agents.
  • Limited to niche resistant cases; total addressable market remains constrained.

Regulatory and Reimbursement Challenges

• FDA approvals: Continuous efforts are underway to expand indications, including data for early-stage HIV, which could broaden the market.

• Reimbursement: CMS and private payers reimburse based on resistant HIV case severity; coverage depends on clinical justification.

• Manufacturing and supply: Scalability ensures consistent supply, maintaining market confidence.

Strategic Opportunities

• Combination regimens: Development of fixed-dose combinations to improve adherence.

• Policy advocacy: Targeting inclusion in standard-of-care guidelines for resistant HIV.

• Market expansion: Leveraging clinical data to extend indications to broader HIV populations.

---

Key Takeaways

• TROGARZO is a niche drug targeting MDR-HIV, with limited but growing market share.
• Revenue growth hinges on expanding indications, resistance trends, and pricing.
• Competitive dynamics favor integrase inhibitors, but TROGARZO's unique mechanism sustains its relevance in resistant cases.
• Reimbursement and regulatory actions will influence its market trajectory.
• Its high price limits widespread adoption but underscores its importance in specialized HIV treatment.

---

FAQs

1. What is the primary mechanism of TROGARZO?

   It is a monoclonal antibody that binds to the CD4 receptor, preventing HIV-1 entry into immune cells.

2. In what patient population is TROGARZO primarily used?

   It treats adults with multidrug-resistant HIV-1 who have limited treatment options.

3. What are the main competitors to TROGARZO?

   Other antiretrovirals, particularly integrase inhibitors like Dolutegravir, dominate the market but are less effective in resistant cases.

4. What is the estimated market size for TROGARZO?

   Estimated at $100-150 million annually in the U.S., with potential to reach $300-400 million depending on resistance trends and extensions of indications.

5. What are the challenges in expanding TROGARZO's market?

   High cost, limited to resistant populations, and competition from other drug classes.

---

References

[1] CDC. (2021). HIV Surveillance Report. Centers for Disease Control and Prevention.

[2] ClinCalc. (2022). Drug Pricing and Cost Data.

[3] FDA. (2020). Approval documents for Ibalizumab.

[4] IQVIA. (2023). Market Data on HIV Drugs.